Vaccination of rabbits with an alkylated toxoid rapidly elicits potent neutralizing antibodies against botulinum neurotoxin serotype B.
New Zealand White (NZW) rabbits were immunized with several different nontoxic botulinum neurotoxin serotype B (BoNT/B) preparations in an effort to optimize the production of a rapid and highly potent, effective neutralizing antibody response. The immunogens included a recombinant heavy chain (rHc) protein produced in Escherichia coli, a commercially available formaldehyde-inactivated toxoid, and an alkylated toxoid produced by urea-iodoacetamide inactivation of the purified active toxin. All three immunogens elicited an antibody response to BoNT/B, detected by enzyme-linked immunosorbent assay (ELISA) and by toxin neutralization assay, by the use of two distinct mouse toxin challenge models. The induction period and the ultimate potency of the observed immune response varied for each immunogen, and the ELISA titer was not reliably predictive of the potency of toxin neutralization. The kinetics of the BoNT/B-specific binding immune response were nearly identical for the formaldehyde toxoid and alkylated toxoid immunogens, but immunization with the alkylated toxoid generated an approximately 10-fold higher neutralization potency that endured throughout the study, and after just 49 days, each milliliter of serum was capable of neutralizing 10(7) 50% lethal doses of the toxin. Overall, the immunization of rabbits with alkylated BoNT/B toxoid appears to have induced a neutralizing immune response more rapid and more potent than the responses generated by vaccination with formaldehyde toxoid or rHc preparations.
Held
Daniel M
DM
Biosciences Division, SRI International, 333 Ravenswood Ave., Menlo Park, CA 94025, USA.
Shurtleff
Amy C
AC
Fields
Scott
S
Green
Christopher
C
Fong
Julie
J
Jones
Russell G A
RG
Sesardic
Dorothea
D
Buelow
Roland
R
Burke
Rae Lyn
RL
D000477:Alkylating Agents / Q000494:pharmacology; D000818:Animals; D000907:Antibodies, Bacterial / Q000097:blood / Q000276:immunology; D057134:Antibodies, Neutralizing / Q000097:blood* / Q000276:immunology; D001905:Botulinum Toxins / Q000276:immunology* / Q000633:toxicity; D019274:Botulinum Toxins, Type A; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D007460:Iodoacetamide / Q000494:pharmacology*; D051379:Mice; D009500:Neutralization Tests; D011817:Rabbits; D013997:Time Factors; D014121:Toxoids / Q000008:administration & dosage* / Q000737:chemistry / Q000276:immunology
D000477:Alkylating Agents; D000907:Antibodies, Bacterial; D057134:Antibodies, Neutralizing; D014121:Toxoids; C096323:rimabotulinumtoxinB; D001905:Botulinum Toxins; D019274:Botulinum Toxins, Type A; D007460:Iodoacetamide
Infect Immun. 1991 Feb;59(2):625-30
1702767
Protein Expr Purif. 2004 Mar;34(1):8-16
14766296
Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11346-50
12177434
Vaccine. 2007 May 22;25(21):4273-82
17395341
Protein Expr Purif. 2004 Mar;34(1):95-102
14766304
Infect Immun. 2003 May;71(5):2941-4
12704175
Comp Immunol Microbiol Infect Dis. 2009 Mar;32(2):107-21
18243312
Nat Biotechnol. 2007 Jan;25(1):107-16
17173035
Infect Immun. 2008 Jan;76(1):437-42
17967862
Protein Expr Purif. 2006 Apr;46(2):256-67
16297638
Crit Rev Immunol. 2007;27(4):303-18
18197811
Cell Res. 2002 Jun;12(2):157-60
12118942
J Pharm Technol. 1989 Jul-Aug;5(4):181-6
10314382
Clin Infect Dis. 1996 Aug;23(2):337-40
8842274
Protein Expr Purif. 2006 Feb;45(2):288-95
16143544
Microbiol Rev. 1982 Mar;46(1):86-94
6806598
Curr Top Microbiol Immunol. 1995;195:55-75
8542759
Infect Immun. 2007 Jun;75(6):3043-54
17371853
J Clin Microbiol. 1988 Nov;26(11):2351-6
3235662
Cloning Stem Cells. 2007 Spring;9(1):12-6
17386007
J Cell Sci. 1999 Aug;112 ( Pt 16):2715-24
10413679
Crit Rev Microbiol. 2005;31(1):11-8
15839401
Infect Immun. 1995 Jul;63(7):2738-42
7790092
J Protein Chem. 2000 Aug;19(6):475-87
11195972
J Protein Chem. 2000 Nov;19(8):699-707
11307955
Biologicals. 2006 Sep;34(3):223-6
16490362
Vaccine. 2002 Jun 7;20(19-20):2556-61
12057613
J Clin Microbiol. 1989 Aug;27(8):1906-8
2768475
Toxicon. 2006 Sep 1;48(3):246-54
16870221
Infect Immun. 2008 Mar;76(3):1314-8
18070903
J Immunol Methods. 2008 Aug 20;337(1):42-8
18571196
Vaccine. 2007 Oct 23;25(43):7540-8
17897756
Trends Biochem Sci. 2002 Nov;27(11):552-8
12417130